Robert J. Adelman is 10% Owner at Akero Therapeutics, Inc. (AKRO). They have made 5 open-market trades across 4 companies since 2007, most recently 2023-09-19.
CIK 0001329161
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $6.0M since 2007, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELEV | SELL | 2022-05-25 | 2022-05-27 | $4.12 | $5.8M | -35.3% | -50.5% | -57.4% |
| MTCR | BUY | 2020-09-18 | 2020-09-22 | $13.00 | $3.0M | -6.0% | -15.0% | -26.3% |
| AKRO | SELL | 2020-02-28 | 2020-03-03 | $22.77 | $731K | -18.0% | -16.5% | +8.8% |
| AKRO | SELL | 2020-01-02 | 2020-01-06 | $19.71 | $1.4M | -5.1% | +25.6% | -2.2% |
| ARYX | BUY | 2007-11-13 | 2007-11-14 | $10.00 | $3.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.